Thursday 7th February we will spend with potential investors and partners together with 14 participating companies from Umeå. It's the annual Biotech Umeå Investment Day 2019. We are looking forward to this event since we are at the stage of finding investors for our exciting progress towards a new drug against chronic inflammatory diseases. We [...]
According to Johnson & Johnson there are still tons of opportunity in the immunology market, even though it´s crowded. Jennifer Taubert, executive vice president and worldwide pharma chairman recently said at the J.P. Morgan Healthcare Conference: “We do look at immunology as being very, very attractive, and in certain areas, there’s so much unmet medical [...]
"Sweden is number eight on the list of European countries that receive the most money" says Johan Lindberg at Vinnova, who helps Swedish companies to apply for EU grants. So far, Sweden has received SEK 10 billion through the EU Innovation Fund Horizon 2020, of which 25 million was allocated to Lipum for the development [...]
Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development. The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic inflammatory diseases. To further increase the momentum we are now raising additional funding by a share issue. Interested investors get a chance to join the [...]
A range of CMO partners have been evaluated for cell line development and production of Lipum’s antibody. Next weeks our CEO and CMC Project Manager will travel to both Europe and the US visiting contract manufacturers before selecting this critical collaboration partner. To be continued ...
An article from Biostock In the northern of Sweden, Umeå, the privately owned company Lipum wants to draw the game plan for the treatment of chronic inflammatory diseases. The main assets are a new drug candidate and promising preclinical result for a unique target molecule. BioStock has met CEO Einar Pontén and discussed the past year [...]
An opportunity for investors on Thursday the 7th of February 2019. An efficient full day of exclusive one-to-one partnering at the Biotech Umeå Investment Day 2019. Book your meeting with Lipum at Grand Hôtel in Stockholm. In addition, you can meet with up to 14 different life science companies that are in early development or [...]
Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén and our CMC Project Manager Mats Reslow at BIO-Europe 2018 in Copenhagen, Nov 5-7. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these [...]
Press release Aug 29, 2018 Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases. Lipum has identified the novel target [...]
Lipum and some listed nordic life science companies will make company presentations in Stockholm at Nyhetsbyrån Direkt on August 29, 2018. The event is organised by Biostock and will also be broadcasted with start at 09:00. It is free of charge, sign up here.